Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC
Hossein Borghaei, DO, MS, discusses unique characteristics of EGFR exon 20 insertion mutations in non–small cell lung cancer.
EP: 1.Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC
EP: 2.Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer
EP: 3.Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP: 4.Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities
EP: 5.Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer
EP: 6.Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP: 7.Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC
EP: 8.Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC
EP: 9.Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC
EP: 10.Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC
EP: 11.Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
EP: 12.Uncommon EGFR Mutations in Non–Small Cell Lung Cancer
Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, professor, Department of Hematology/Oncology, co-director, Immune Monitoring Facility, Lung Cancer and Mesothelioma TRDG member, and Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Fox Chase Cancer Center, discusses unique characteristics of EGFR exon 20 insertion mutations in non–small cell lung cancer (NSCLC).
Next-generation sequencing panels are able to identify EGFR exon 20 insertions; however, the mutation is not as common as EGFR exon 19 or exon 21 mutations, says Borghaei.
Notably, patients who harbor EGFR exon 20 insertions do not respond to traditional TKIs that are commonly utilized for EGFR-positive patients, Borghaei explains. Additionally, these mutations are biologically different from traditional EGFR mutations, says Borghaei. As such, developing novel therapies that specifically target EGFR exon 20 insertions has been an area of ongoing research, Borghaei concludes.
